The TP508 Solution for Respiratory Failure (ARDS)

Respiratory Failure (ARDS)
Acute respiratory distress syndrome (ARDS) affects more than 3 million people each year globally and ~180,000 patients in the US, accounting for 10% of intensive care unit admissions, of which the mortality rate is ~30%. The Global ARDS Market in 2019 (prior to COVID) was $620 million. It is projected to be approximately $1 billion in 2027. To date, there are no effective pharmacological therapies specifically approved for ARDS. ARDS is characterized by poor oxygenation, pulmonary infiltrates, and acuity of onset. On a microscopic level, the disorder is associated with diffuse alveolar damage and capillary endothelial injury. The lungs are full of tiny sac-like structures called alveoli. It is in the alveoli where oxygen and carbon dioxide are exchanged between the air inhaled and the blood that perfuses the lungs in tiny vessels called capillaries.
When the lungs are injured, for instance by an infection or traumatic event, inflammatory white blood cells are recruited to the area of injury and fluids leak from the capillaries into the alveoli restricting oxygen passage from the alveoli into blood causing hypoxia, scar tissue formation, and systemic effects that can lead to multi-organ failure and mortality. TP508 is as an injectable drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation.  Because TP508 can affect cellular processes involved in ARDS progression at multiple points, it has the advantage of potentially showing efficacy where previous candidate drugs have failed.

A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely blocks the viral-induced cytokine storm including upregulation of IL6 and TNFa) in animals expressing the human ACE2 receptor. Thus, TP508 reduces inflammation which mitigates vascular effects of SARS-CoV-2 leading to disease progression, allowing for earlier patient recovery.

Other preclinical studies show that TP508 can prevent vascular changes that are associated with COVID-19 progression.

  • TP508 attenuates neuroinflammation and blood barrier changes induced by radiotherapy and traumatic brain injury.
  • TP508 reverses ischemic effects in the heart following acute myocardial infarct
  • TP508 reduces radiation-induced coagulopathy and hemorrhage in brain, heart and lungs to prevent multiple organ failure.
TP508

TP508 is as an injectable drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. TP508 also activates stem cells to regenerate tissues and restore function. Because TP508 can affect cellular processes involved in ARDS progression at multiple points, it has the advantage of potentially showing efficacy where previous candidate drugs have failed

Brain Cancer
  • Radiation therapy decreases neurogenesis in hippocampus and can lead to permanent mental Impairment
  • 90% of Children under 7 require special education and have learning defects for the rest of their lives
  • Adults experience memory loss (10 to 20% drop in IQ) and increased probability of early dementia
  • No FDA approved product to solve this problem

TP508 brings the hope of preventing RT brain damage

TP508 Therapy
  • Decreases Neuroinflammation
  • Regenerates brain cells
  • Increases neural function
  • Clinical trials expected to show improved memory, cognition, and quality of life
  • Mitigates RT damage to normal tissue to allow oncologists to better eradicate tumors